New and emerging therapies for systemic lupus erythematosus

Eleni Papachristodoulou,Vasileios C Kyttaris
DOI: https://doi.org/10.1016/j.clim.2024.110200
Abstract:Systemic Lupus Erythematosus (SLE) and lupus nephritis treatment is still based on non-specific immune suppression despite the first biological therapy for the disease having been approved more than a decade ago. Intense basic and translational research has uncovered a multitude of pathways that are actively being evaluated as treatment targets in SLE and lupus nephritis, with two new medications receiving FDA approval in the last 3 years. Herein we provide an overview of targeted therapies for SLE including medications targeting the B lymphocyte compartment, intracellular signaling, co-stimulation, and finally the interferons and other cytokines.
What problem does this paper attempt to address?